版本:
中国

U.S. FDA rejects Mylan's generic version of GSK's Advair

March 29 Mylan NV said on Wednesday its application to market a generic copy of GlaxoSmithKline Plc's blockbuster inhaled lung drug Advair was rejected by the U.S. Food and Drug Administration.

The drugmaker did not disclose the reason behind the rejection.

Advair has generated more than $1 billion in annual sales since 2001. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐